Marketing authorization of COVID-19 vaccines across UK, EU, and the US: fact-checking and the implications for future research.
J Pharm Policy Pract
; 14(1): 110, 2021 Dec 24.
Article
in English
| MEDLINE | ID: covidwho-1724579
ABSTRACT
While having access to safe and efficient vaccines is essential for eradicating the COVID-19 pandemic, gaining marketing authorisation is a critical step in enabling and speeding this process. On December 2, 2020, the United Kingdom became the first country to approve the first COVID-19 vaccine. This commentary aims to provide a quick overview of the UK's COVID-19 vaccine authorization process and compare it to that of the EU and the US. While the UK, EU, and US expedited the COVID-19 vaccine approval process, regulatory authorities did not appear to cut corners in their approval of the Pfizer COVID-19 vaccine, as evidenced by their decisions to switch emergency use authorization to full authorization in the US and to renew conditional/temporary use authorization in the EU and UK, respectively. There is an opportunity to conduct a thorough investigation into and comparison of the filed dossiers, as well as the robustness of the evaluation process for the approval of COVID-19 vaccines.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
Topics:
Vaccines
Language:
English
Journal:
J Pharm Policy Pract
Year:
2021
Document Type:
Article
Affiliation country:
S40545-021-00400-0
Similar
MEDLINE
...
LILACS
LIS